Center-Authored Papers

Filters: Author is LeBlanc, Michael  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea DB, Press OW, Constine LS, Barton KP, Friedberg JW et al..  2015.  Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.. Blood. 125(2):236-41. Abstract
Mir MA, Maurer MJ, Ziesmer SC, Slager SL, Habermann T, Macon WR, Link BK, Syrbu S, Witzig T, Friedberg JW et al..  2015.  Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma.. Blood. 125(6):992-8. Abstract
Whole-Body Irradiation
Thompson JA, Fisher RI, LeBlanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A.  2008.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz. Blood. 111(8):4048-54. Abstract
Viral Vaccines
Yoo GH, Moon J, LeBlanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J et al..  2009.  A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Archives of otolaryngology--head & neck surgery. 135(9):869-74. Abstract
Vincristine
Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, Shea TC, Porcu P, Winter JN, Kahl BS et al..  2013.  Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma.. The New England journal of medicine. 369(18):1681-90. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI.  2006.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(25):4143-9. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.  2003.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.. Blood. 102(5):1606-12. Abstract
Rimsza LM, LeBlanc M, Unger JM, Miller TP, Grogan TM, Persky DO, Martel RR, Sabalos CM, Seligmann B, Braziel RM et al..  2008.  Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.. Blood. 112(8):3425-33. Abstract
Persky DO, Miller TP, Unger JM, Spier CM, Puvvada S, Stea DB, Press OW, Constine LS, Barton KP, Friedberg JW et al..  2015.  Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313.. Blood. 125(2):236-41. Abstract
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.  2005.  New treatment options have changed the survival of patients with follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(33):8447-52. Abstract
Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP.  2008.  Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(14):2258-63. Abstract
Venous Thrombosis
Dai JY, LeBlanc M, Smith NL, Psaty B, Kooperberg C.  2009.  SHARE: an adaptive algorithm to select the most informative set of SNPs for candidate genetic association.. Biostatistics (Oxford, England). 10(4):680-93. Abstract
Vascular Cell Adhesion Molecule-1
Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, LeBlanc M, Fisher RI, Miller TP.  2009.  A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108.. Leukemia & lymphoma. 50(5):728-35. Abstract
United States
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI.  2006.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(25):4143-9. Abstract
Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SD.  2015.  The diffusion of docetaxel in patients with metastatic prostate cancer.. Journal of the National Cancer Institute. 107(2) Abstract
Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP.  2005.  New treatment options have changed the survival of patients with follicular lymphoma.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(33):8447-52. Abstract
Seymour L, Ivy PS, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, LeBlanc M, Stewart D, Crowley J et al..  2010.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9. Abstract
Tumor Markers, Biological
Seymour L, Ivy PS, Sargent D, Spriggs D, Baker L, Rubinstein L, Ratain MJ, LeBlanc M, Stewart D, Crowley J et al..  2010.  The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(6):1764-9. Abstract
Hoering A, LeBlanc M, Crowley J.  2008.  Randomized phase III clinical trial designs for targeted agents.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(14):4358-67. Abstract
Treatment Outcome
Dai JY, LeBlanc M, Kooperberg C.  2009.  Semiparametric estimation exploiting covariate independence in two-phase randomized trials.. Biometrics. 65(1):178-87. Abstract
Yoo GH, Moon J, LeBlanc M, Lonardo F, Urba S, Kim H, Hanna E, Tsue T, Valentino J, Ensley J et al..  2009.  A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Archives of otolaryngology--head & neck surgery. 135(9):869-74. Abstract
LeBlanc M, Rankin C, Crowley J.  2009.  Multiple Histology Phase II Trials.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15(13):4256-62. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Fisher RI.  2006.  Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(25):4143-9. Abstract
Thompson JA, Fisher RI, LeBlanc M, Forman SJ, Press OW, Unger JM, Nademanee AP, Stiff PJ, Petersdorf SH, Fefer A.  2008.  Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomiz. Blood. 111(8):4048-54. Abstract
Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, Gaynor ER, Rivkin SE, Fisher RI.  2003.  A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.. Blood. 102(5):1606-12. Abstract